The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis

Rupesh Agrawal, Bjorn Kaijun Betzler, Ilaria Testi, Sarakshi Mahajan, Aniruddha Agarwal, Dinesh Visva Gunasekeran, Dhananjay Raje, Kanika Aggarwal, Somasheila I. Murthy, Mark Westcott, Soon Phaik Chee, Peter McCluskey, Su Ling Ho, Stephen Teoh, Luca Cimino, Jyotirmay Biswas, Shishir Narain, Manisha Agarwal, Padmamalini Mahendradas, Moncef KhairallahNicholas Jones, Ilknur Tugal-Tutkun, Kalpana Babu, Soumayava Basu, Ester Carreño, Richard Lee, Hassan Al-Dhibi, Bahram Bodaghi, Alessandro Invernizzi, Debra A. Goldstein, Talin Barisani-Asenbauer, Julio J. González-López, Sofia Androudi, Reema Bansal, Bruttendu Moharana, Simona Degli Esposti, Anastasia Tasiopoulou, Sengal Nadarajah, Mamta Agarwal, Sharanaya Abraham, Ruchi Vala, Ramandeep Singh, Aman Sharma, Kusum Sharma, Manfred Zierhut, Onn Min Kon, Emmett T. Cunningham, John H. Kempen, Quan Dong Nguyen, Carlos Pavesio, Vishali Gupta*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose: Tubercular intermediate uveitis (TIU) and panuveitis (TBP) are difficult to manage because of limitations in diagnostic tools and lack of evidence-based treatment guidelines. The Collaborative Ocular Tuberculosis Study (COTS) analyzed treatment regimens and therapeutic outcomes in patients with TIU and TBP. Methods: Multicentre retrospective analysis. Results A total of 138 TIU and 309 TBP patients were included. A total of 382 subjects received antitubercular therapy (ATT) (n = 382/447; 85.4%) and 382 received corticosteroids (n = 382/447; 85.4%). Treatment failure was observed in 78 individuals (n = 78/447; 17.4%), occurring less frequently in patients receiving ATT (n = 66/382; 17.2%) compared to those who did not (n = 12/65; 18.5%). The study did not show any statistically significant therapeutic effect of ATT in patients with TIU and TBP. Conclusion Taking into account the limitations of the retrospective, non-randomized study design, resultant reliance on reported data records, and unequal size of the samples, the current study cannot provide conclusive evidence on the therapeutic benefit of ATT in TIU and TBP.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - 2020

Keywords

  • Anti-tubercular therapy
  • collaborative ocular tuberculosis study (COTS)
  • ocular tuberculosis
  • tubercular intermediate uveitis
  • tubercular panuveitis
  • tubercular uveitis
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis'. Together they form a unique fingerprint.

Cite this